Lavipharm Financial Statements From 2010 to 2024
| LAVI Stock | EUR 0.86 0.03 3.61% |
Check Lavipharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lavipharm main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Lavipharm financial statements analysis is a perfect complement when working with Lavipharm Valuation or Volatility modules.
Lavipharm |
Lavipharm SA Company Profit Margin Analysis
Lavipharm's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Lavipharm Profit Margin | 0.02 % |
Most of Lavipharm's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lavipharm SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Lavipharm SA has a Profit Margin of 0.0248%. This is 100.22% lower than that of the Healthcare sector and 99.84% lower than that of the Drug Manufacturers - Major industry. The profit margin for all Greece stocks is 101.95% lower than that of the firm.
Lavipharm SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lavipharm's current stock value. Our valuation model uses many indicators to compare Lavipharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lavipharm competition to find correlations between indicators driving Lavipharm's intrinsic value. More Info.Lavipharm SA is currently regarded as number one stock in return on asset category among related companies. It is currently regarded as number one stock in profit margin category among related companies fabricating about 0.62 of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for Lavipharm SA is roughly 1.63 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Lavipharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lavipharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lavipharm's earnings, one of the primary drivers of an investment's value.About Lavipharm Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Lavipharm income statement, its balance sheet, and the statement of cash flows. Lavipharm investors use historical funamental indicators, such as Lavipharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lavipharm investors may use each financial statement separately, they are all related. The changes in Lavipharm's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lavipharm's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lavipharm Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lavipharm. Please read more on our technical analysis and fundamental analysis pages.
Lavipharm S.A. develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. Lavipharm S.A. was founded in 1911 and is based in Paiania, Greece. LAVIPHARM operates under Drug Manufacturers - Major classification in Greece and is traded on Athens Stock Exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lavipharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lavipharm's short interest history, or implied volatility extrapolated from Lavipharm options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lavipharm Correlation against competitors. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Lavipharm Stock analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |